Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities - PubMed (original) (raw)
. 1996 Mar 8;271(10):5309-12.
doi: 10.1074/jbc.271.10.5309.
Affiliations
- PMID: 8621380
- DOI: 10.1074/jbc.271.10.5309
Free article
Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities
X Liu et al. J Biol Chem. 1996.
Free article
Abstract
The c-ret proto-oncogene encodes a receptor tyrosine kinase which plays an important role in neural crest as well as kidney development. Genetic studies have demonstrated that germ line mutations in the ret oncogene are the direct cause of multiple endocrine neoplasia (MEN) 2A and 2B, familial medullary thyroid carcinoma (FMTC), and Hirschsprung's disease. However, despite the large body of genetic and biological evidence suggesting the importance of RET in development and neoplastic processes, the signal transduction mechanisms of RET remain unknown. To begin to understand the molecular mechanisms of the disease states caused by mutations in RET, the patterns of autophosphorylation of the wild-type RET and the MEN mutants were studied using site-directed mutagenesis and phosphopeptide mapping. Among the 6 autophosphorylation sites found in the wild-type RET receptor, the MEN2B mutant lacked phosphorylation at Tyr-1096, leading to decreased Grb2 binding, while simultaneously creating a new phosphorylation site. These changes in autophosphorylation suggest that the MEN2B mutation may result in the more aggressive MEN2B phenotype by altering the receptor's signaling capabilities.
Similar articles
- Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase.
Marshall GM, Peaston AE, Hocker JE, Smith SA, Hansford LM, Tobias V, Norris MD, Haber M, Smith DP, Lorenzo MJ, Ponder BA, Hancock JF. Marshall GM, et al. Cancer Res. 1997 Dec 1;57(23):5399-405. Cancer Res. 1997. PMID: 9393766 - Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
Carlomagno F, Melillo RM, Visconti R, Salvatore G, De Vita G, Lupoli G, Yu Y, Jing S, Vecchio G, Fusco A, Santoro M. Carlomagno F, et al. Endocrinology. 1998 Aug;139(8):3613-9. doi: 10.1210/endo.139.8.6124. Endocrinology. 1998. PMID: 9681515 - Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
Salvatore D, Melillo RM, Monaco C, Visconti R, Fenzi G, Vecchio G, Fusco A, Santoro M. Salvatore D, et al. Cancer Res. 2001 Feb 15;61(4):1426-31. Cancer Res. 2001. PMID: 11245446 - Putting the bits and pieces of the RET proto-oncogene puzzle together.
Gagel RF. Gagel RF. Bone. 1995 Aug;17(2 Suppl):13S-16S. doi: 10.1016/8756-3282(95)00200-w. Bone. 1995. PMID: 8579892 Review. - Oncogenic activation of the ret protooncogene in thyroid cancer.
Takahashi M. Takahashi M. Crit Rev Oncog. 1995;6(1):35-46. doi: 10.1615/critrevoncog.v6.i1.30. Crit Rev Oncog. 1995. PMID: 8573606 Review.
Cited by
- FOXA2 and STAT5A regulate oncogenic activity of KIF5B-RET fusion.
Lee MR, Shin JY, Kim MY, Kim JO, Jung CK, Kang J. Lee MR, et al. Am J Cancer Res. 2023 Feb 15;13(2):638-653. eCollection 2023. Am J Cancer Res. 2023. PMID: 36895965 Free PMC article. - Rare manifestation of multiple endocrine neoplasia type 2A & cutaneous lichen amyloidosis in a family with RET gene mutation.
Birla S, Singla R, Sharma A, Tandon N. Birla S, et al. Indian J Med Res. 2014 May;139(5):779-81. Indian J Med Res. 2014. PMID: 25027091 Free PMC article. No abstract available. - Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C, Tigu AB, Munteanu R, Moldovan CS, Kegyes D, Onaciu A, Gulei D, Ghiaur G, Einsele H, Croce CM. Tomuleasa C, et al. Signal Transduct Target Ther. 2024 Aug 14;9(1):201. doi: 10.1038/s41392-024-01899-w. Signal Transduct Target Ther. 2024. PMID: 39138146 Free PMC article. Review. - Molecular mechanisms of RET activation in human neoplasia.
Santoro M, Carlomagno F, Melillo RM, Billaud M, Vecchio G, Fusco A. Santoro M, et al. J Endocrinol Invest. 1999 Nov;22(10):811-9. doi: 10.1007/BF03343650. J Endocrinol Invest. 1999. PMID: 10614534 Review. No abstract available. - A Drosophila model of multiple endocrine neoplasia type 2.
Read RD, Goodfellow PJ, Mardis ER, Novak N, Armstrong JR, Cagan RL. Read RD, et al. Genetics. 2005 Nov;171(3):1057-81. doi: 10.1534/genetics.104.038018. Epub 2005 Jun 18. Genetics. 2005. PMID: 15965261 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous